FDA approves use of Vascepa-assisted therapy to reduce the risk of cardiovascular disease

recently, the FDA announced that it has approved the use of Vascepa as an ancillary treatment to reduce the risk of cardiovascular disease in adults with triglyceride levels above 150 mg/dL.

about the VascepaVascepa is the first FDA-approved complementary therapy to be used as a maximum to-dosage statin to reduce triglyceride levels and increase the risk of cardiovascular disease in patients.Vascepa is made up of high-purity iosapent ethyl, derived from the natural fish oil ingredient omega-3 fatty acids, and is produced using FDA-regulated manufacturing processes to remove impurities and retain active ingredients.Vascepa is a prescription drug that the FDA identifies as a new chemical entity rather than a dietary supplement like regular fish oil.Vascepa's unique clinical characteristics have enabled it to obtain a number of patents internationally, including the ability to reduce triglyceride levels in patients without increasing LDL-C levels.Vascepa has been approved by the FDA to reduce triglyceride levels in patients with severe high triglycerides.Vascepa's effectiveness and safety was supported by a study of 8,179 patients over the age of 45 with a history of coronary arteries, cerebrovascular, cervical arteries, and peripheral artery obstruction disorders, or over 50 years of age with diabetes and other cardiovascular risk factors.Patients treated with Vascepa were significantly less likely to have cardiovascular events, such as a stroke or heart attack. (Drug Information Network)